How do the revised rules in the Bipartisan Budget Act of 2015 affect you and your business?
“We anticipate that operating losses will occur and substantially increase over the next several years as we expand discovery, research and development activities, including clinical development of our Tarmogen product candidates,” the company wrote in its earnings report.
Sponsor Generated Content
In July, GlobeImmune – which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C – went public, pricing its shares at $10 apiece and raising $17.3 million in gross proceeds.
The company’s shares have steadily declined since hitting a high point of $14.79 on July 11. They were trading at $8.62 by mid-afternoon Friday, down 7 percent from the previous day’s close.